Rybelsus®

Semaglutide

Rybelsus® tablets (semaglutide) is a prescription medicine used in adults with type 2 diabetes mellitus to decrease blood sugar levels. Rybelsus® can be prescribed when other diabetes medicines have been tried without success and should be used together with diet and exercise. Rybelsus® tablets work to lower blood sugar (glucose) levels by increasing how much insulin is released and decreasing glucagon secretion. This medicine also may slow gastric emptying after eating.
more
Package Per pill Price Savings Order
90 tablet
Free AirMail shipping Hot
lei 71.76
lei 6458.30lei 71.76
lei 860.66
60 tablet
Free AirMail shipping Hot
lei 76.54
lei 4592.50lei 76.54
lei 286.81
30 tablet
Free AirMail shipping Hot
lei 81.32
lei 2439.65lei 81.32
Package Per pill Price Savings Order
90 tablet
Free AirMail shipping Hot
lei 86.11
lei 7750.00lei 86.11
lei 430.09
60 tablet
Free AirMail shipping Hot
lei 88.50
lei 5310.11lei 88.50
lei 143.28
30 tablet
Free AirMail shipping Hot
lei 90.89
lei 2726.70lei 90.89
Package Per pill Price Savings Order
90 tablet
Free AirMail shipping Hot
lei 102.86
lei 9256.99lei 102.86
lei 430.09
60 tablet
Free AirMail shipping Hot
lei 105.25
lei 6314.77lei 105.25
lei 143.28
30 tablet
Free AirMail shipping Hot
lei 107.63
lei 3229.03lei 107.63
Rybelsus

Brand(s)

Manufacturer

  • Novo Nordisc India Pvt. Ltd

Disease(s)

  • Type 2 Diabetes Mellitus / High Blood Sugar

Rybelsus® tablets

What is Rybelsus?

Rybelsus tablets (semaglutide) is a prescription medicine used in adults with type 2 diabetes mellitus to decrease blood sugar levels. Rybelsus can be prescribed when other diabetes medicines have been tried without success, and should be used together with diet and exercise.

Rybelsus tablets work to lower blood sugar (glucose) levels by increasing how much insulin is released and decreasing glucagon secretion. This medicine also may slow gastric emptying after eating. Rybelsus is from the class of medicines called GLP-1 receptor agonists.
Rybelsus is not for treating type 1 diabetes.
Rybelsus was first approved by the FDA on September 20, 2019.

Warnings

You should not use Rybelsus if you have multiple endocrine neoplasia type 2 (tumors in your glands), a personal or family history of medullary thyroid cancer, insulin-dependent diabetes, or diabetic ketoacidosis.
Call your doctor at once if you have signs of a thyroid tumor, such as swelling or a lump in your neck, trouble swallowing, a hoarse voice, or shortness of breath.